TYCC
SPRO icon

Texas Yale Capital Corp’s Spero Therapeutics SPRO Stock Holding History

Texas Yale Capital Corp’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$23.3K – 517
2025
Q4 		$23.3K Hold
10,000
– – ﹤0.01% 491
2025
Q3 		$18.8K Hold
10,000
– – ﹤0.01% 481
2025
Q2 		$29K Hold
10,000
– – ﹤0.01% 462
2025
Q1 		$7.2K Hold
10,000
– – ﹤0.01% 451
2024
Q4 		$10.3K Buy
+10,000
New +$11.9K ﹤0.01% 459
2024
Q3 		– Sell
-10,000
Closed -$13K – 462
2024
Q2 		$13K Hold
10,000
– – ﹤0.01% 438
2024
Q1 		$17.2K Hold
10,000
– – ﹤0.01% 440
2023
Q4 		$14.7K Hold
10,000
– – ﹤0.01% 431
2023
Q3 		$12.1K Hold
10,000
– – ﹤0.01% 420
2023
Q2 		$14.5K Hold
10,000
– – ﹤0.01% 439
2023
Q1 		$14.5K Hold
10,000
– – ﹤0.01% 448
2022
Q4 		$17.3K Buy
+10,000
New +$18.7K ﹤0.01% 449

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Texas Yale Capital Corp's SPRO Position: Q1 2026 in Review

Texas Yale Capital Corp sold out of Spero Therapeutics (SPRO) in Q1 2026, closing a stake of 10,000 shares — an estimated $23.3K sold.

Texas Yale Capital Corp first reported a position in SPRO in Q4 2022 and held it in 12 quarters. The position peaked at $29K in Q2 2025. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Texas Yale Capital Corp reported no remaining Spero Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Texas Yale Capital Corp sold 10,000 Spero Therapeutics shares in Q1 2026, an estimated $23.3K.
  • Texas Yale Capital Corp first reported a position in Spero Therapeutics in Q4 2022 and held it in 12 quarters.
  • Texas Yale Capital Corp's Spero Therapeutics position peaked at $29K in Q2 2025.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Texas Yale Capital Corp's 13F filing for Q1 2026, filed 4 May 2026.